Navigation Links
GeoVax Labs, Inc. Plans Public Offering
Date:3/1/2010

ATLANTA, March 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company, today announced that it intends to file a registration statement for the sale of $20.0 million or more of its common stock. The offering may also include shares to be sold by selling stockholders, although no arrangements have been made. The purpose of the offering would be to raise funds to enable the Company to develop its vaccines business.

The Company anticipates filing the registration statement some time after it has filed its Annual Report on Form 10-K for the year ended December 31, 2009.  The timing of the offering will be determined at a later date, depending on several factors, including market conditions and when the registration statement is eligible to be declared effective by the SEC.

This press release is being issued in accordance with Rule 135 of the Securities Act of 1933, as amended.  THIS PRESS RELEASE IS NEITHER AN OFFER TO SELL NOR A SOLICITATION OF OFFERS TO PURCHASE COMMON STOCK.  A REGISTRATION STATEMENT RELATING TO THE COMMON STOCK OF THE COMPANY HAS NOT YET BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.  THE OFFER, IF COMMENCED, WILL BE MADE ONLY BY THE PROSPECTUS TO BE INCLUDED IN THE REGISTRATION STATEMENT

Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether the SEC will declare the proposed registration statement to be effective and when, whether the Company will be able to sell its common stock on terms acceptable to it or at all, market conditions, and factors over which GeoVax has no control, including those described in the Company's most recent Annual Report on Form 10-K and its other SEC filings and reports. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so, unless otherwise required by law.

SOURCE GeoVax Labs, Inc.

Back to top

RELATED LINKS
http://www.geovax.com

'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
2. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
3. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
4. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
5. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
6. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
7. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. GeoVax Secures $10 Million Financing Commitment
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
11. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):